A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) (CMV)

A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers

AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV).

The objectives of this Phase 1 study are to test the safety of the vaccine and the immune response to the vaccine in healthy volunteers who have not previously been infected with CMV. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in each arm on three occasions over 6 months. The study will last 12 months and will have a total of 12 visits.

Study Overview

• Status: Completed
• Conditions: Cytomegalovirus Infections
• Intervention / Treatment: Biological: AVX601; Biological: AVX601; Biological: AVX601; Biological: AVX601; Biological: AVX601; Biological: Placebo; Biological: Placebo

Detailed Description

This is a randomized, double-blind, placebo-controlled Phase 1 study of the safety and immunogenicity of AVX601 vaccine at two dosage levels and two routes of administration in healthy volunteers conducted at a single research center. A total of 40 participants will be enrolled into two groups of 20 participants each. Within each group, participants will be randomized to receive the active vaccine by IM injection (N = 8) or SC injection (N = 8) or to receive a placebo by IM injection (N = 2) or SC injection (N = 2). Each participant will receive a total of six injections of vaccine or placebo, two at each visit at Weeks 0, 8 and 24, administered by a study nurse in an outpatient setting, and will be followed for 12 months after the first immunization. Safety data will include local and systemic reactogenicity after each dose of vaccine, collected in a systematic format using a subject memory aid and a standard grading scale, specific safety laboratory parameters and general AEs. Immunogenicity data will be obtained by collecting blood at defined time points before and after immunization and separating serum (for measurement of antibodies to CMV by ELISA and neutralization assays and to the vaccine vector by a VRP neutralization assay) and peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses to CMV peptides).

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Cincinnati Center for Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Between 18 and 45 years of age, inclusive
2. Good general health without significant physical examination findings or clinically significant abnormal laboratory results
3. Available to participate for the entire study period of approximately 12 months
4. For women of childbearing potential, a negative urine pregnancy test at screening and before each immunization, and agreement to consistently use contraception from 28 days prior to enrollment until the last protocol visit, for sexual activity that could lead to pregnancy

5. Acceptable laboratory parameters:

   • negative CMV serology
   • hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for men
   • white blood cell count 3,300 - 12,000 cells/mm3
   • platelet count 125,000 - 550,000/mm3
   • alanine aminotransferase (ALT) within normal range for study laboratory
   • serum creatinine within normal range for study laboratory
   • normal urine dipstick (negative glucose, negative hemoglobin, and negative or trace protein)
   • negative hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests
   • negative HIV blood test
6. Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to CMV or the alphavirus vector if such assays become available
7. Willingness to participate in the study as evidenced by signed informed consent obtained before screening

Exclusion Criteria:

1. Venous access deemed inadequate for the phlebotomy demands of the study
2. Women who are breast feeding
3. In female subjects, a positive urine pregnancy test at screening or on the day of any vaccine injection
4. Receipt of any vaccine within 30 days prior to enrollment
5. Use of any investigational agent within 30 days prior to enrollment
6. Receipt of immunoglobulin or blood products within 60 days prior to enrollment
7. Use of cytotoxic medications within 6 months prior to enrollment
8. Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
9. History of serious adverse reactions to any vaccine, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema or abdominal pain
10. History of immunodeficiency or autoimmune disease
11. History of diabetes mellitus
12. History of splenectomy
13. History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
14. Psychiatric condition that may interfere with the ability to comply with the protocol requirements. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
15. History of medical, occupational or family problems as a result of alcohol or illicit drug use during the past 12 months
16. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: T4	Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Active Comparator: T1	Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C1	Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the SC route
Active Comparator: T2	Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C2	Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the SC route
Active Comparator: T3	Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C3	Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: AVX601; 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Placebo Comparator: C4	Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the IM route; Biological: Placebo; 3 doses of placebo given at T=0, 8, 24 weeks via the SC route

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
evaluate safety of AVX601 based on teh frequency of Grade 2,3,or 4 systemic reactogenicity events	1 year

Secondary Outcome Measures

Outcome Measure	Time Frame
evaluate the immunogenicity of AVX601 in healthy volunteers after 3 doses of vaccine	15 months

Collaborators and Investigators

• Sponsor: AlphaVax, Inc.
• Investigators: Principal Investigator: Robert A Olmsted, Ph.D., AlphaVax, Inc.

Publications and helpful links

Helpful Links

• AlphaVax Human Vaccines, Inc.

Study record dates

Study Major Dates

• Study Start: April 1, 2007
• Primary Completion (Actual): July 1, 2008
• Study Completion (Actual): July 1, 2008

Study Registration Dates

• First Submitted: February 23, 2007
• First Submitted That Met QC Criteria: February 23, 2007
• First Posted (Estimate): February 26, 2007

Study Record Updates

• Last Update Posted (Estimate): November 10, 2008
• Last Update Submitted That Met QC Criteria: November 7, 2008
• Last Verified: November 1, 2008

More Information

Terms related to this study

• Keywords: cytomegalovirus; CMV; Alphavirus
• Additional Relevant MeSH Terms: Virus Diseases; Infections; DNA Virus Infections; Herpesviridae Infections; Cytomegalovirus Infections
• Other Study ID Numbers: AVX601-001